香港亞洲醫療集團完成碧桂園創投領投4億美元D輪融資
香港亞洲醫療集團近日完成D輪融資,由碧桂園創投及春華資本領投,泰康人壽、工銀國際、農銀國際、交銀國際、Hudson Bay、夏爾巴投資跟投,現有股東君聯資本及泛大西洋投資等亦有參與,涉資4億美元。
碧桂園創投董事總經理孫梁浩表示,碧桂園創投長期關注健康領域,而心腦血管疾病為常見慢性非傳染性疾病,死亡率及診療技術難度高,亞洲地區疾病人群基數大,認為亞洲醫療集團擁有國內民營體系頂級診療技術及優秀專業醫療團隊,未來將持續支持企業發展,陪伴其成長為亞洲頂尖醫療品牌,惠及更多患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.